JP2014506234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014506234A5 JP2014506234A5 JP2013538989A JP2013538989A JP2014506234A5 JP 2014506234 A5 JP2014506234 A5 JP 2014506234A5 JP 2013538989 A JP2013538989 A JP 2013538989A JP 2013538989 A JP2013538989 A JP 2013538989A JP 2014506234 A5 JP2014506234 A5 JP 2014506234A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- blood
- polyoxyethylene
- molecular weight
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000003743 erythrocyte Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 27
- 238000001802 infusion Methods 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 208000014674 injury Diseases 0.000 claims description 15
- 239000012141 concentrate Substances 0.000 claims description 11
- 230000008733 trauma Effects 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 10
- 208000007502 anemia Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000010444 Acidosis Diseases 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 3
- 208000019838 Blood disease Diseases 0.000 claims description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims description 3
- 206010021113 Hypothermia Diseases 0.000 claims description 3
- 208000034486 Multi-organ failure Diseases 0.000 claims description 3
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000007950 acidosis Effects 0.000 claims description 3
- 208000026545 acidosis disease Diseases 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 208000014951 hematologic disease Diseases 0.000 claims description 3
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 3
- 230000002631 hypothermal effect Effects 0.000 claims description 3
- 230000000302 ischemic effect Effects 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 206010051895 acute chest syndrome Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- -1 polyoxyethylene Polymers 0.000 claims 22
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 11
- 229920001451 polypropylene glycol Polymers 0.000 claims 11
- 229920001577 copolymer Polymers 0.000 claims 5
- 230000002209 hydrophobic effect Effects 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 2
- 239000013542 high molecular weight contaminant Substances 0.000 claims 2
- 239000013541 low molecular weight contaminant Substances 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000287 tissue oxygenation Effects 0.000 description 7
- 206010040047 Sepsis Diseases 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000007675 cardiac surgery Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000000399 orthopedic effect Effects 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000008343 sublingual microcirculation Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010068048 S-nitrosohemoglobin Proteins 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 238000001320 near-infrared absorption spectroscopy Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41351910P | 2010-11-15 | 2010-11-15 | |
| US61/413,519 | 2010-11-15 | ||
| PCT/US2011/060747 WO2012068079A1 (en) | 2010-11-15 | 2011-11-15 | Methods for enhancing oxygenation of jeopardized tissue |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015199281A Division JP2016041714A (ja) | 2010-11-15 | 2015-10-07 | 危険にさらされた組織のオキシジェネーション増進方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014506234A JP2014506234A (ja) | 2014-03-13 |
| JP2014506234A5 true JP2014506234A5 (https=) | 2015-06-25 |
| JP5823530B2 JP5823530B2 (ja) | 2015-11-25 |
Family
ID=46084364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538989A Active JP5823530B2 (ja) | 2010-11-15 | 2011-11-15 | 危険にさらされた組織のオキシジェネーション増進方法 |
| JP2015199281A Pending JP2016041714A (ja) | 2010-11-15 | 2015-10-07 | 危険にさらされた組織のオキシジェネーション増進方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015199281A Pending JP2016041714A (ja) | 2010-11-15 | 2015-10-07 | 危険にさらされた組織のオキシジェネーション増進方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20130177524A1 (https=) |
| EP (1) | EP2640684A4 (https=) |
| JP (2) | JP5823530B2 (https=) |
| KR (2) | KR20150124457A (https=) |
| CN (1) | CN103328427A (https=) |
| AU (1) | AU2011329088B2 (https=) |
| BR (1) | BR112013011858A2 (https=) |
| CA (1) | CA2817542A1 (https=) |
| CL (1) | CL2013001382A1 (https=) |
| EA (1) | EA201390720A1 (https=) |
| IL (1) | IL226285A0 (https=) |
| MX (1) | MX2013005457A (https=) |
| NZ (1) | NZ610441A (https=) |
| PE (1) | PE20140134A1 (https=) |
| SG (1) | SG190695A1 (https=) |
| WO (1) | WO2012068079A1 (https=) |
| ZA (1) | ZA201303416B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2817542A1 (en) * | 2010-11-15 | 2012-05-24 | Mast Therapeutics, Inc. | Methods for enhancing oxygenation of jeopardized tissue |
| GB201207543D0 (en) * | 2012-05-01 | 2012-06-13 | Haemair Ltd | Treatment of transfusion blood |
| CA2927361A1 (en) * | 2013-10-16 | 2015-04-23 | Mast Therapeutics, Inc. | Diuretic induced alterations of plasma volume |
| KR102525493B1 (ko) | 2014-07-07 | 2023-04-25 | 라이프래프트 바이오사이언시즈 인코포레이티드 | 장기 순환 물질이 없는 폴록사머 조성물 및 이의 제조 방법 및 용도 |
| WO2016007542A1 (en) | 2014-07-07 | 2016-01-14 | Mast Therapeutics, Inc. | Poloxamer therapy for heart failure |
| US9757411B2 (en) | 2014-07-07 | 2017-09-12 | Aires Pharmaceuticals, Inc. | Poloxamer therapy for heart failure |
| RU2760324C1 (ru) * | 2018-12-10 | 2021-11-24 | Елена Валентиновна Аршинцева | Новое применение полоксамера в качестве фармакологически активного вещества |
| CN118076227A (zh) * | 2021-08-18 | 2024-05-24 | 欧姆尼奥克斯股份有限公司 | 用于器官保存的h-nox蛋白 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041288A (en) | 1986-05-15 | 1991-08-20 | Emory University | Method of treating tissue damaged by reperfusion injury |
| US4897263A (en) | 1986-05-15 | 1990-01-30 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5064643A (en) | 1986-05-15 | 1991-11-12 | Emory University | Method for treating sickle cell disease |
| US4837014A (en) | 1986-05-15 | 1989-06-06 | Emory University | An improved method of treating sickle cell anemia |
| US5039520A (en) | 1986-05-15 | 1991-08-13 | Emory University | Plasma extender |
| US4879109A (en) | 1986-05-15 | 1989-11-07 | Emory University | Method for treating burns |
| US5030448A (en) | 1986-05-15 | 1991-07-09 | Emory University | Method of delivering drugs to damaged or diseased tissue |
| US5017370A (en) | 1986-05-15 | 1991-05-21 | Emory University | Improved method of performing angioplasty procedures |
| US5028599A (en) | 1986-05-15 | 1991-07-02 | Emory University | Method of treating mycardial damage |
| US4937070A (en) | 1986-05-15 | 1990-06-26 | Emory University | Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids |
| US5047236A (en) | 1986-05-15 | 1991-09-10 | Emory University | Method of treating stroke |
| US5089260A (en) | 1986-05-15 | 1992-02-18 | Emory University | Method of treating ischemic tissue |
| US5080894A (en) | 1986-05-15 | 1992-01-14 | Emory University | Method and composition for reducing tissue damage |
| US5032394A (en) | 1986-05-15 | 1991-07-16 | Emory University | Method of treating burns |
| US5078995A (en) | 1986-05-15 | 1992-01-07 | Emory University | Fibrionolytic composition |
| US4997644A (en) | 1986-05-15 | 1991-03-05 | Emory University | Method of treating adult respiratory distress syndrome |
| US4801452A (en) | 1986-05-15 | 1989-01-31 | Hunter Robert L | Fibrinolytic composition |
| US5071649A (en) | 1986-05-15 | 1991-12-10 | Emory University | Method of preventing blockage in catheters |
| US4873083A (en) | 1986-05-15 | 1989-10-10 | Emory University | Fibrinolytic composition |
| US5696298A (en) | 1991-03-19 | 1997-12-09 | Cytrx Corporation | Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| ATE187154T1 (de) * | 1991-03-19 | 1999-12-15 | Cytrx Corp | Polyoxypropylen/polyoxyethylen copolymere mit verbesserter biologischer aktivität |
| US5605687A (en) | 1992-05-15 | 1997-02-25 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for repair of electrical injury |
| US7087369B2 (en) * | 2003-12-17 | 2006-08-08 | The Regents Of The University Of California | Cornea preservation medium |
| AU2005289520A1 (en) * | 2004-09-27 | 2006-04-06 | Vical Incorporated | Formulations and methods for treatment of inflammatory diseases |
| JP2010535772A (ja) * | 2007-08-10 | 2010-11-25 | シンスラックス インコーポレイテッド | 慢性的微小血管障害を治療するためのポリマー療法 |
| CA2817542A1 (en) * | 2010-11-15 | 2012-05-24 | Mast Therapeutics, Inc. | Methods for enhancing oxygenation of jeopardized tissue |
-
2011
- 2011-11-15 CA CA2817542A patent/CA2817542A1/en not_active Abandoned
- 2011-11-15 AU AU2011329088A patent/AU2011329088B2/en active Active
- 2011-11-15 KR KR1020157030550A patent/KR20150124457A/ko not_active Ceased
- 2011-11-15 EP EP11841387.1A patent/EP2640684A4/en not_active Withdrawn
- 2011-11-15 JP JP2013538989A patent/JP5823530B2/ja active Active
- 2011-11-15 SG SG2013035449A patent/SG190695A1/en unknown
- 2011-11-15 NZ NZ610441A patent/NZ610441A/en unknown
- 2011-11-15 PE PE2013001082A patent/PE20140134A1/es not_active Application Discontinuation
- 2011-11-15 MX MX2013005457A patent/MX2013005457A/es not_active Application Discontinuation
- 2011-11-15 BR BR112013011858A patent/BR112013011858A2/pt not_active IP Right Cessation
- 2011-11-15 KR KR1020137015206A patent/KR20130097795A/ko not_active Ceased
- 2011-11-15 WO PCT/US2011/060747 patent/WO2012068079A1/en not_active Ceased
- 2011-11-15 EA EA201390720A patent/EA201390720A1/ru unknown
- 2011-11-15 CN CN2011800648610A patent/CN103328427A/zh active Pending
-
2013
- 2013-03-01 US US13/783,158 patent/US20130177524A1/en not_active Abandoned
- 2013-05-09 IL IL226285A patent/IL226285A0/en unknown
- 2013-05-10 ZA ZA2013/03416A patent/ZA201303416B/en unknown
- 2013-05-15 CL CL2013001382A patent/CL2013001382A1/es unknown
-
2014
- 2014-11-25 US US14/553,913 patent/US20150093368A1/en not_active Abandoned
-
2015
- 2015-10-07 JP JP2015199281A patent/JP2016041714A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014506234A5 (https=) | ||
| Rawal et al. | Anemia in intensive care: a review of current concepts | |
| Kreimeier et al. | Hemodilution in clinical surgery: state of the art 1996 | |
| Klein et al. | Red blood cell transfusion in clinical practice | |
| JP5823530B2 (ja) | 危険にさらされた組織のオキシジェネーション増進方法 | |
| Arya et al. | Blood component therapy: which, when and how much | |
| JPH11507378A (ja) | 酸素飽和状態（ｏｘｇｅｎａｔｉｏｎ ｓｔａｔｕｓ）をモニターすることによって簡便化された血液希釈法 | |
| Seishi et al. | Effect of the cellular-type artificial oxygen carrier hemoglobin vesicle as a resuscitative fluid for prehospital treatment: experiments in a rat uncontrolled hemorrhagic shock model | |
| Ayhan et al. | The effects of non-leukoreduced red blood cell transfusions on microcirculation in mixed surgical patients | |
| US7267817B2 (en) | Method for improving oxygen transport by stored red blood cells | |
| Dennis et al. | Transfusion of 2, 3 DPG-enriched red blood cells to improve cardiac function | |
| Kasper et al. | Failure of autologous fresh frozen plasma to reduce blood loss and transfusion requirements in coronary artery bypass surgery | |
| CN104159591A (zh) | 红细胞的处理 | |
| Gottschall et al. | Thrombotic thrombocytopenic purpura: experience with whole blood exchange transfusion | |
| Hequet et al. | Red blood cell exchange in an emergency in sickle cell disease | |
| Standl | Artificial oxygen carriers as red blood cell substitutes–perfluorocarbons and cell-free hemoglobin | |
| Castro et al. | Improved method for automated red cell exchange in sickle cell disease | |
| Korhan | Miniaturized Extracorporeal Circuits: Innovative Approaches in Cardiac Surgery | |
| EP4590312A1 (en) | Oxygen reduced blood for use in the treatment of traumatic brain injury accompanied by hemorrhagic shock | |
| Pillay | Comparative in vitro analysis of a balanced electrolyte solution versus an unbalanced electrolyte solution, for processing of Residual pump blood using Cell saver for patients undergoing Elective cardiac Surgery | |
| Beyea | NH 03756, USA e-mail: howard. l. corwin@ hitchcock. org | |
| Anthony et al. | Indications for Transfusion | |
| Litty et al. | Use of Blood Products | |
| Gibbs | Blood and Blood Products | |
| Corwin et al. | Anemia, blood transfusion, and erythropoietin in the critically ill |